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Introduction: The application of mesenchymal stem cells (MSCs) in treating rheumatoid arthritis (RA) has been made
possible by the immunosuppressive and differentiation abilities of these cells. A non-invasive means of assessing cell
integration and bio-distribution is fundamental in evaluating the risks and success of this therapy, thereby enabling
clinical translation. This paper defines the use of superparamagnetic iron oxide nanoparticles (SPIONs) in conjunction
with magnetic resonance imaging (MRI) to image and track MSCs in vivo within a murine model of RA.
Methods: Murine MSCs (mMSCs) were isolated, expanded and labelled with SiMAG, a commercially available particle.
In vitro MRI visibility thresholds were investigated by labelling mMSCs with SiMAG with concentrations ranging from 0
to 10 μg/ml and resuspending varying cell doses (103 to 5 × 105 cells) in 2 mg/ml collagen prior to MR-imaging.
Similarly, in vivo detection thresholds were identified by implanting 3 × 105 mMSCs labelled with 0 to 10 μg/ml SiMAG
within the synovial cavity of a mouse and MR-imaging. Upon RA induction, 300,000 mMSCs labelled with SiMAG
(10 μg/ml) were implanted via intra-articular injection and joint swelling monitored as an indication of RA development
over seven days. Furthermore, the effect of SiMAG on cell viability, proliferation and differentiation was investigated.
Results: A minimum particle concentration of 1 μg/ml (300,000 cells) and cell dose of 100,000 cells (5 and 10 μg/ml)
were identified as the in vitro MRI detection threshold. Cell viability, proliferation and differentiation capabilities were
not affected, with labelled populations undergoing successful differentiation down osteogenic and adipogenic
lineages. A significant decrease (P < 0.01) in joint swelling was measured in groups containing SiMAG-labelled and
unlabelled mMSCs implying that the presence of SPIONs does not affect the immunomodulating properties of the
cells. In vivo MRI scans demonstrated good contrast and the identification of SiMAG-labelled populations within the
synovial joint up to 7 days post implantation. This was further confirmed using histological analysis.
Conclusions: We have been able to monitor and track the migration of stem cell populations within the rheumatic
joint in a non-invasive manner. This manuscript goes further to highlight the key characteristics (biocompatible and the
ability to create significant contrast at realistic doses within a clinical relevant system) demonstrated by SiMAG that
should be incorporated into the design of a new clinically approved tracking agent.Introduction
Current tissue engineering approaches focusing on restor-
ing and regenerating articular cartilage damage are limited
to the damage caused by trauma and osteoarthritis [1].
The chronic inflammatory environment of the rheumatic
arthritic joint renders these techniques ineffective, as
similarly to the original native cartilage, newly formed* Correspondence: a.j.el.haj@keele.ac.uk
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reproduction in any medium, provided the orcartilage will again undergo destruction within the hostile
environment [1]. Rheumatoid arthritis (RA, a chronic
autoimmune disease) is characterised by pain, stiffness
and inflammation of the synovial joint [1-3]. This results in
the destruction of articular cartilage and affects approxi-
mately 1% of the global population [1,2,4,5]. Current RA
treatments involve a combination of drug regimens to
alleviate symptoms, such as pain and inflammation,
while preserving joint function and maintaining quality of
life [1,5]. Few patients have experienced complete drugal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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joint function and regenerating cartilage [1,5,6].
Advances in tissue engineering have emphasised the role
of mesenchymal stem cells (MSCs) in treating autoimmune
diseases, such as RA [1,2,7]. Their specific self-renewal,
multipotent differentiation ability (osteoblasts, chondro-
cytes and adipocytes), migratory, anti-inflammatory and
immunosuppresssive properties are all key characteristics
linked to their success in stem cell-based therapies
[1,2,8-10]. These are modulated by the secretion of bio-
active molecules. The immunosuppressive properties of
MSCs are of particular importance in treating autoimmune
diseases, such as RA [1]. The release of cytokines and
growth factors, such as IL-10, IL-6, IL-11 and transforming
growth factor – β (TGF-β), acts to inhibit T cells and
dendritic cells [7,11] while the secretion of soluble antigens,
such as human leukocyte antigen G (HLA-G), effectively
disables natural killers and moderate dendritic cell and
T cell activity. In addition, secreted immunosuppressive
enzymes, such as indoleamine 2, 3-dioxygenase (IDO),
suppress leukocytes such as B cells [7,11]. The combined
secretion of these factors, their role in tissue homeostasis
and repair (governed by a signalling mechanism) [2] and
the cartilage forming ability of MSCs provides a trophic
regenerative environment, stimulating the proliferation and
differentiation of tissues to achieve intrinsic repair while
protecting the neo tissue in a localised immunosuppressive
manner [1,7,11].
Very little is known of the in vivo events occurring post
implantation. A means of imaging and tracking implanted
MSCs could prove extremely valuable in evaluating and
optimising mechanisms of cartilage repair within an inflam-
matory environment. Information linked to cell migration
[12], rate of repair [12] and tissue integration are pivotal in
optimising the therapy in terms of cell number [13], cell
dose [12], dosage schemes [14] and delivery methods [12].
Traditional means of gathering such data have relied on
histological tests on sacrificed animals [15-17]. This tends
to be invasive and information limited. The shortcomings
of these techniques render them unacceptable in assessing
the success of the cellular therapies [15-17].
In response to this, superparamagnetic iron oxide nano-
particles (SPIONs) can be employed in conjunction with
the use of magnetic resonance imaging (MRI) to track im-
planted cells in vivo [16,18,19]. To date, little work has been
carried out to optimise SPION concentrations for specific
tissue applications in vivo. To this end, we have optimised
towards the current clinical MRI modalities commonly
found in hospitals, these being 1.5 tesla (T) and 3 T scan-
ners. In essence, stem cells are encouraged to internalise
SPIONs; through this method, the magnetic properties of
the particles are transferred to the cells. The intracellular
iron disturbs the local magnetic field thus allowing cells to
be visualised as a lack of signal with MRI [19-25].Here we have adopted a murine model of RA to investi-
gate the immunomodulating and anti-inflammatory prop-
erties of mouse MSCs (mMSCs) labelled with and without
SPIONs and to optimise the in vivo imaging and tracking
protocol. To our knowledge, this is the first time MSCs
have been tracked using SPIONS within a rheumatic joint
in this manner.
Materials and methods
Mice
Experiments were undertaken in either 7- to 10-week-old
inbred C57Bl/6 or BALB/c mice as specified (Harlan,
Bicester UK). Procedures were performed in accordance
with Home Office-approved project licence PPL 40/
3594 and were approved by the Ethical Review Commit-
tee at Liverpool John Moores University UK, February
2012.
Cells
mMSCs were isolated from BALB/c mice as previously
described [26]. In brief, femurs and tibias were removed
and flushed to isolate bone marrow cells. Cells were sub-
sequently plated and incubated in cell isolation media
(CIM) (RPMI-1640; Lonza, Slough UK) supplemented
with 9% fetal bovine serum (FBS; Lonza, Biowhittakar),
9% horse serum, 1% penicillin-streptomycin (Gibco, Paisley
UK) and cultured under standard conditions for 24 hours.
Non-adherent cells were then removed and four weeks
later cells re-plated at a seeding density of 100 cells per
cm2 in complete expansion media (CEM; Iscove Modified
Dulbecco Medium (IMDM); Invitrogen, Paisley UK)
supplemented with 9% FBS, 9% horse serum and 1%
penicillin-streptomycin for MSC expansion.
Cell labelling
SPIONS
mMSCs were labelled with SiMAG (a commercially
available particle, 1,000 nm particle size) (Chemicell,
Berlin Germay). These particles have an unmodified
silica surface with terminal negatively charged silanol
groups. Cells were labelled at either passage (P) 12 or 13
using a 24 hour passive incubation method in serum free -
CIM. Following incubation, 3 × PBS washes were per-
formed in order to remove excess particles attached to the
surface of the cells and flask.
CM-DiI labelling
Briefly, a stock solution of the fluorescent cell-tracer CM-
DiI (Molecular Probes, Paisley UK) was prepared in di-
methyl sulfoxide (DMSO) at a concentration of 1 mg/ml.
MSCs were trypsinised, washed with PBS and incubated
in the working solution of CM-DiI for five minutes at 37°C,
and then for an additional 15 minutes at 4°C, in the dark.
Unincorporated dye was removed via centrifugation (300 g
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in serum-free IMDM and maintained at 4°C until injection.
Cell characterisation
Differentiation
SiMAG-labelled MSCs were tested for their ability to
undergo differentiation into osteocytes and adipocytes.
Labelled cells were incubated (37°C, 5% CO2) for a period
of 21 days in the relevant differentiation media. Adipo-
genic media: CEM supplemented with Insulin, Transfer-
rin, Selenium Premix (ITS), 1:100, Sigma-Aldrich, Dorset,
UK), dexamethesome (10-6 M), 3-isobutyl-1-methylaxa-
nithine (0.5 μM, Sigma – Aldrich, Dorset UK) and
indomethacin (100 μM, Sigma Aldrich). Osteogenic media;
CEM supplemented with dexamethesome (10-8 M, Sigma –
Aldrich), β – glycerophosphate (10 mM, Sigma –
Aldrich) and ascorbate – 2- phosphate (88 ng/ml,
Sigma – Aldrich). After three weeks of culture in differ-
entiation media, cells were fixed (95% methanol, 15
minutes) and stained with the relevant histological dyes
including: Oil Red O (stain for lipids) prepared using
0.18% Oil red ‘O’ (Sigma –Aldrich) prepared in 10%
isopropyl alcohol (IPA). Calcium deposition was con-
firmed by an Alizarin red dye prepared using 1% Alizarin
Red solution (Sigma – Aldrich) (pH 4).
Flow cytometry analysis (fluorescence activated cell sorting)
Murine MSCs, labelled with or without SiMAG were
analysed for membrane receptor expression. Antibodies
used in this study were as follows: anti-mouse CD31
(PECAM-1) PE, anti-human/mouse CD44 PE, anti-mouse
CD11b PE, anti-mouse CD45 PE, anti-mouse CD105 PE,
anti-mouse Ly-6A(Sca-1)PE (all from eBioscience Hatfield
UK). Cells were incubated at 4°C for 30 minutes with the
relevant antibody. As a negative control, cells were in-
cubated with the isotype antibodies. Propidium iodide
staining was included in the immunophenotyping to
evaluate the viability of the cells. A minimum of 10,000
events were recorded for each analysis, using a FACScan
flow cytometer and analysed using CellQuestPro software
(Becton Dickinson, Oxford, UK).
Viability and proliferation
MTT
The effect of particle labeling on the proliferation rate of
mMSCs was investigated using the MTT assay (a tetrazo-
lium salt; Sigma). The MTT assay specifically determines
cell number as a function of mitochondrial activity.
SiMAG-labelled mMSCs (10 μg/ml) were allowed to
expand up to 24 hours and 7 days, after which point, 0.5
mg/ml MTT solution was added to each sample and incu-
bated for 4 hours at 37°C. The MTT solution was removed
and DMSO added to solubilise the MTT crystals for a
further 10 minutes at 37°C. Negative control groups weretreated with DMSO for 5 minutes. Aliquots (200 μl) of the
resultant assay solution were transferred to a 96-well plate
and absorbance (570/690; excitation/emission) was read
using the Syngery 2 Biotek plate reader. Sample repeats
were n = 3.
Live dead assessment
Cell viability was investigated using live/dead assay.
SiMAG-labelled mMSCs (10 μl/ml) were allowed to
expand up to 24 hours and 7 days before being treated
with 1% calcein AM and 2% propidium iodide prepared
in PBS according to the manufacturer’s instructions for 45
minutes at 37°C, whilst protected from light. Samples
were imaged using a UV fluorescent microscope (Nikon
Eclipse Ti-S).
Quantification of particle uptake
Prussian blue
mMSCs labeled with SIMAG (10 μg/ml) were fixed and
permeabilised using 95% methanol for 15 minutes at room
temperature. Cells were then treated with a solution made
of a 1:1 ratio of 20% aqueous solution of HCl and 10%
aqueous solution of potassium ferrocyanide (20 minutes,
room temperature) (n = 3). Cells were imaged with a light
microscope (Nikon – Eclipse TS 100).
Inductively coupled plasma optical emission spectrometry
Inductively coupled plasma optical emission spectrometry
(ICP - OEAS) was performed to quantify the uptake of
particles by mMSCs. A total of 300,000 cells were labelled
with SiMAG (10 μg/ml) (n = 3). Labelled cells were
collected and immersed in 1 ml of concentrated analytical
grade nitric acid and heated to 60°C overnight for the
degradation of particles in order to release Fe content.
Samples were then diluted with dH20 to achieve a final
acid concentration of less than 10% prior to analysis
using ICP.
Induction of murine antigen-induced arthritis
Experiments were performed in seven- to eight-week-old
male C57B1 mice. Murine antigen-induced arthritis (AIA)
was induced as described [27]. Briefly, mice were immu-
nised subcutaneously with 1 mg/ml of methylated BSA
emulsified with an equal volume of Freund’s complete
adjuvant and injected intraperitoneally with 100 μl
heat-inactivated Bordetella pertussis toxin (Sigma-Aldrich,
Poole, UK). The immune response was boosted one week
later. Twenty-one days after the initial immunisation,
murine AIA was induced by intra-articular (IA) injection
of 10 mg/ml mBSA in the right knee joint. Left knee joints
were treated as controls by receiving PBS injections.
Twenty hours after arthritis induction, 10 μl of serum
free CEM, containing 300,000 MSCs either labelled with
or without SiMAG (10 μg/ml) were injected IA into the
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serum free CEM. Explanation of the experimental groups
can be found in Table 1. Upon experiment termination,
animals were sacrificed, prepared for MRI and joints
collected for histological assessment.
Animals were inspected daily for arthritis development
by measuring knee joint diameters using a digital microm-
eter. The difference in joint diameter between the arthritic
(right) and non-arthritic control (left) knee in each animal
gave a quantitative measure of swelling (in mm). Statistical
analysis was performed using unpaired t-test.
Magnetic resonance imaging
Evaluating minimum visibility threshold
In vitro minimum visibility was investigated by resuspend-
ing mMSC labelled with 0, 1, 5 and 10 μg/ml SiMAG at
various cell dosages (103, 104, 105, 3 × 105, 5 × 105) in 2
mg/ml rat tail type I collagen (BD Biosciences, Oxford
UK). Samples were MR imaged using a Brucker 2.3 T
animal scanner (Nottingham Trent University). The re-
laxation parameters T1 and T2
eff were estimated for
each of the samples. T2
eff was estimated using a Multi Slice
Multi Spin Echo (MSME) imaging sequence and fitted ex-
ponential to the envelope of the echoes. The repetition
time was set at five seconds and the echo time at the low-
est value, 10.173 ms. A matrix size of 256 × 128 gave a
spatial resolution of (0.35 × 0.55) mm. T1 was estimated
using the same sequence with a repetition time varied
between 100 and 5,000 ms and fitted exponential to the
first echo in the train of each image.
Similarly, the in vivo visibility threshold was investigated
by injecting 3 × 105 cells labelled with 0, 1, 5 and 10 μg/ml
SiMAGIA into both joints of healthy (non- arthritic)
10-week-old BALB/c mice (N = 2) and MR imaged on
the same system. In order to improve the contrast around
the joints the two imaging sequences chosen were Rapid
Acquisition with Refocused Echoes (RARE) and Gradient-
echo Fast Imaging (GEFI) for T1 and T2
eff, respectively.
Sequence parameters were as follows: RARE, matrix size:
256 × 192, spatial resolution: (0.47 × 0.42) mm, repetition
time: 4,000 ms, effective echo time: 21.8 ms; GEFI, matrix
size: 256 × 256, spatial resolution: (0.47 × 0.47) mm, repe-
tition time: 500 ms, echo time: 4.7 ms, flip angle: 30°.Table 1 Explanations of experimental groups
Group Description Tracking period
1 (n=6) SiMAG-labelled mMSCs 3 days
2 (n=5) SiMAG-labelled mMSCs 7 days
3 (n=6) Unlabelled mMSCs 3 days
4 (n=5) Unlabelled mMSCs 7 days
5 (n=6) No cells + No Particles (control) 3 days
6 (n=5) No cells + No Particles (control) 7 days
mMSCs, murine mesenchymal stem cells.Magnetic resonance imaging tracking
Mice were sacrificed either three or seven days post cell
implantation and imaged using a Brucker 2.3 T animal
scanner (Nottingham Trent University). Whole body Fat
Low Angle Shot (FLASH) and RARE sequences (detailed
above) were employed to image day three groups while
GEFI and RARE were used for day seven groups to deter-
mine the location of the particle-labelled cells. FLASH,
matrix size: 256 × 256, spatial resolution: (0.45 × 0.29)
mm, repetition time: 1000 ms, echo time: 3.35 ms.
Histological assessment
Animals were sacrificed at the indicated times after
induction of arthritis. Joints were fixed in neutral buffered
formal saline and decalcified with formic acid at 4°C before
embedding in paraffin. Mid-sagittal serial sections (7 μm
thickness) were cut and stained with H & E. For detection
of CM-DiI and SiMAG labelled mMSCs, sections were
rehydrated through xylene and alcohol, stained with fluor-
escent dye (4', 6-diamino-2-phenylindole dihydrochloride
(DAPI), Sigma-Aldrich), mounted in Hydromount (National
Diagnostics, Hessle UK) and imaged using a UV fluor-
escent microscope (Nikon Eclipse Ti-S). Prussian blue
staining was subsequently carried out to identify the pres-
ence of SiMAG labelled cells within joint sections while
toluidine blue staining was used to assess cartilage
damage.
Results
Particle uptake
Particle uptake following a 24 hour passive incubation
period of SiMAG with mMSCs was confirmed by Prussian
blue staining (Figure 1). Internalised particles were stained
blue and were visible within the cell. Intracellular Fe
content was measured by ICP as 20 ± 0.04 pg/cell. Cells
retained morphology post labelling.
Evaluating minimum visibility threshold
Figure 2 demonstrates the relationship between SiMAG
concentration and cell number in terms of MRI signal loss
or hypointensity. Hypointense regions of signal voids high-
light the presence of SiMAG-labelled cells. As expected,
hypointensity increases with cell number and SiMAG
concentration (Figure 2A). T2
eff was found to be shorter
for higher numbers of labelled cells with this further
decreasing with increasing SiMAG concentration from
1 μg/ml to 10 μg/ml (Figure 2B (i,ii)). MRI detection
thresholds were investigated both in vitro and in vivo and
set at a T2
eff value of 0.084 ms in vitro. This corresponded
to a minimum SiMAG concentration of 1 μg/ml (300,000
cells) and a minimum cell dose of 100,000 cells (5 and 10
μg/ml). In essence, any cell: particle combination that
results in a T2
eff value of 0.084 ms or below will be visible
by MRI. The T2
eff at 1,000 cells labelled with 1 μg/ml
Figure 1 Evaluation of morphology and SiMAG uptake by mMSCs. A) Unlabelled mMSCs, B) SiMAG-labelled mMSCs, C) Prussian blue stain
of SiMAG-labelled cells; (i) x 20 magnification, (ii) x 40 magnification. Bars =100 μm. mMSC, murine mesenchymal stem cells.
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This is likely due to poor distribution of the small
number of cells. There is a strong exponential relationship
between the number of cells at each of the concentrations
tested and T2
eff whilst no variation was seen with T1
(Figure 2C (i, ii)).
In vivo dose response was assessed by analysing signal
profiles when 300,000 mMSCs labelled with 0, 1, 5 and 10
μg/ml SiMAG were injected within the synovial cavity of a
mouse (Figure 3). Signal intensity (SI) across the hypo-
intense region was read, plotted and compared (Figure 3A).
A greater loss in signal over a greater area was measured in
mice injected with 5 and 10 μg/ml SiMAG, with an overall
SI loss of 61% and 78% respectively. A less obvious drop in
SI was noticed for mice injected with 1 μg/ml when com-
pared to the control mouse with a SI loss of 20%.
In vitro assessment of SiMAG labelling on mMSC
characterisation, differentiation, viability and proliferation
mMSCs either labelled with SiMAG (10 μg/ml) or with-
out SiMAG underwent successful differentiation towards
osteogenic and adipogenic lineages after 21 days in culture
with relevant differentiation media. Calcium deposition
was stained positive by Alizarin red in both labelled and
unlabelled cells confirming osteogenesis (Figure 4A,C).
Adipogenesis was confirmed by the presence of lipid and
triglyceride droplets stained positive with oil red O after 21
days for SiMAG-labelled and unlabelled cells (Figure 4B,D).
MTT (Figure 4E) and live dead (Figure 4F) analysis re-
vealed no diminished viability and proliferation capacity for
SiMAG-labelled cells at either 24 hours or 7 days with no
significant differences in metabolic activity between treated
and untreated groups at either 24 hours nor 7 days. The
significant increase (P <0.005) in metabolic activity from
24 hours to 7 days as exhibited by both groups highlights
the proliferative capabilities of labelled and unlabelled cells
as counter validated by live dead analysis (Figure 4F).
Fluorescence activated cell sorting (FACS) analysis
demonstrated that mMSCs were negative for hematopoietic
markers CD11b and CD45, the endothelial cell marker
CD31 (PECAM), and positive for the mesenchymalmarkers CD44 and CD105, including the stem cell
marker Sca-1. Propidium iodide staining confirmed a
cell viability of >95% for both SiMAG-labelled and un-
labelled cell populations. Labelling cells with SiMAG did
not have an effect on the immunophenotype of mMSC
(Figure 4G).
Rheumatoid arthritis progression (joint swelling)
This model (AIA) has previously been used to investigate
the therapeutic effects of mMSCs in the arthritic mouse
by measuring joint swelling (mm) as a clinical indication
of joint inflammation (Kehoe et al.). Upon RA induction
(day 0), knee swelling (mean ± SEM in mm) increased to
approximately 1.5 (three day study) and 1.1 (seven day
study) times that of the control knee (left). IA administra-
tion of either SiMAG labelled or unlabelled mMSCs on day
one resulted in an immediate decrease in joint swelling in
both studies with a significant drop in swelling measured
on day two in the three day study (SiMAG labeled, 0.8
mm, unlabelled mMSCs 0.8 mm versus control group, 1.23
mm) and day three of the seven day study (SiMAG labelled,
0.46 mm, unlabelled mMSCs 0.45 mm versus control
group, 0.78 mm). This trend continued in the three day
study (SiMAG labelled, 0.6 mm, unlabelled mMSCs 0.5
mm versus control group, 0.9 mm) and ultimately in the
seven day study (SiMAG labelled, 0.12 mm, unlabelled
mMSCs 0.18 mm versus control group, 0.45 mm). The
joint swelling in the control groups is seen to increase in
the seven day study from 0.3 mm on day five to 0.45 mm
on day seven (Figure 5).
In vivo tracking – magnetic resonance imaging and
histological analysis
Sacrificed mice were MR imaged on days three and seven
using FLASH and GEFI sequences respectively. Hypoin-
tense signal voids were observed over the diseased knee
(right) in groups 1 and 2 (Figure 6B (i) and 6 (ii)). This
represents mMSCs labelled with 10 μg/ml of SiMAG and
is shown graphically by plotting signal loss profiles and
comparing the signal of the right (diseased) to the left
(untreated) joint. It can be noticed that the signal drops
Figure 2 In vitro dose response. A) T2
eff map for 1, 5 and 10 μg/ml SiMAG-labelled cells ranging in cell doses (103, 104, 105, 3 × 105, 5 × 105).
B) Bar chart depicting i) T2 and ii) normalised T1 measurements at each particle concentration (1 to 10 μg/ml) and cell dose (103, 104, 105, 3 × 105,
5×105). Red line indicates MRI visibility threshold implying that any cell: particle combination resulting in a T2 less than 0.084 ms can be detected by
MRI. C) Plot to show correlation between number of cells and i) T2
eff and ii) normalised T1 for three different concentrations (1, 5 and 10 μg/ml) of
SiMAG. Data = average ± SD (n = 6). Assume *** significant levels unless otherwise stated (P <0.005). *Indicates significant statistical difference in T2
between 500,000 cells labelled with either 5 μg/ml or 10 μg/ml (P <0.01). MRI, magnetic resonance imaging; T1, longitudinal relaxation time; T2,
transverse relaxation time; T2eff, effective transverse relaxation time.
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treated with SiMAG-labelled mMSCS as compared to
the left knee (Figure 6A (i) and (ii)). This signal loss is
attributed to the presence of SiMAG-labelled cells. No
signal voids or hypointese regions could be detected in
groups 3 and 4 where unlabelled cells were implanted
(Figure 6B (iii)) nor in groups 5 and 6 where no cells were
implanted at all (Figure 6 (iv)). This is again validated bythe signal loss profiles where similar high-signal profiles are
shown for both the right (diseased) and left (untreated)
joint in (Figure 6A (iii) and (iv)). Immunohistological ana-
lysis of tissue sections revealed the presence of fluorescently
(DIL and DAPI) labelled cells within the synovial joint, spe-
cifically in the lining and sub-lining layers of the synovium,
in the region of the patella, and femoral and tibial surfaces
of all mice in groups 1 to 4, seven days post implantation
Figure 3 In vivo dose response. A) Signal profile and B) corresponding coronal GEFI MR images relating to mMSCs labelled with 0
μg/ml (i), 1 μg/ml (ii), 5 μg/ml (iii) or 10 μg/ml (iv) and implanted within the right knee of each mouse. Red line highlights the area
across which SI was measured. GEFI, gradient-echo fast imaging; mMSCs, murine mesenchymal stem cells; MR, magnetic resonance; SI,
signal intensity.
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found in control groups (Figure 6C (iv) and D i) (iv)).
Further to this, no localisation of implanted cells was
observed in other joint tissues. Prussian blue staining
successfully revealed the presence of iron (stained blue) in
knee sections for groups receiving SiMAG labelled mMSCs
(groups 1 and 2) (Figure 6C (i,ii) and D ii) (i,ii)).
Toluidine blue primarily stains for acidic proteoglycans
found in articular cartilage making it an applicable stain
to assess cartilage depletion in arthritis. Joint sections
highlighted the loss of proteoglycans from the surface of
articular cartilage in the control group (Figure 7iii). Car-
tilage depletion was less pronounced in groups receiving
mMSC treatments after three days (groups 1 and 3).Discussion
In response to the lack of pharmacological interventions
to treat RA, cell therapies have been developed, offering
new opportunities in tackling this disease. Stem cells, such
as MSCs, have been used to regenerate and restore the
function of damaged tissue, such as cartilage [7]. The
striking ability of MSCs to migrate toward the site of
injury, engraft with surrounding tissues [28] and differen-
tiate into cartilage [29] whilst suppressing the immune
system, highlights their applicability as a possible therapy
for RA [2]. Despite the vast number of studies demon-
strating the potential of MSCs in treating RA, the clin-
ical translation and commercialisation of this therapy
is hindered by additional unknown factors [7]. A non-
Figure 4 Immunophenotypic characterization, cell viability, proliferation and differentiation of SiMAG-labelled mMSCS. mMSCs labelled with (C,
D) and without (A, B) SiMAG underwent successful differentiation down osteogenic (A, C) and adipogenic (B, D) lineages after 21 days. mMSCs labelled
with 10 μg/ml of SiMAG characterised at 24 hours and 7 days by E) MTT analysis and F) live dead staining. *** Indicates P <0.001. Bars = 100 μm. (G)
SiMAG-labelled and unlabelled mMSCs were negative for hematopoietic markers CD11b and CD45, endothelial cell marker CD31 and positive for CD44,
CD105and Sca-1. The expression of every antigen is shown together with their corresponding isotype control. mMSCs, murine mesenchymal stem cells.
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therapy in terms of cellular bio distribution [30] and cell
survival [31] is key in deciphering the mechanism of repair,
evaluating the therapeutic effect, grafting location and rul-
ing out potentially dangerous side effects [17]. This would
encourage regulatory approval to be obtained and thera-
peutic potential optimised for clinical applications [28].
The precedent for labelling cells with magnetic nano-
particles (MNPs) or SPIONS comes from the technology
employed in MRI and MRI contrast agents and offers an
attractive way of monitoring cells in vivo [28,32-34].SPIONs are essentially composed of a magnetite (Fe3O4)
or maghemite (γ-Fe2O3) core coated with a biocompatible
polymer [35]. The range of particles commercially available
is vast with particles ranging in size from the nanometer to
the micron scale [17,34] and differing in polymer coating
and surface chemistries. An extensive range of studies uti-
lising an assortment of MNPs have been used for a variety
of tissue engineering studies. There is no clear consensus
as to the ideal MNP size, concentration or magnet strength
that would yield the greatest contrast in vivo. As previously
mentioned, 1.5 and 3 T scanners are commonly found in
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design and optimise imaging and tracking protocols in
terms of cell number and particle concentration to these
clinically relevant scanners. Particle concentration ranging
from 12.5 to 400 μg/ml have been reportedly used in stud-
ies focusing on 1.5 T scanners [16,22,28] while 2.8 to 168
μg/ml have been reported in studies using 3 T scanners
[16,24,31]. In this study, a particle concentration of 10 μg/ml
has been implemented within a 2.3 T scanner highlighting
the clinical relevance of our system.
In recent years, a number of studies focusing on the
development of strategies to image and track stem cells
within the articular joint have emerged. These studies
tend to adopt invasive surgical models of osteoarthritis in
either rabbits or rats where cells (MSCs or chondrocytes)
are labelled with MNPs, seeded onto scaffolds, such as
collagen type I gel [25] or agarose [36], and implanted
within osteochondral defects. Animals are then monitored
over a period ranging from four to twelve weeks while
being MR imaged [13,25,36,37]. Particles used in these
studies have ranged from very small superparamagnetic
iron oxide nanoparticles (11 nm) [25] to Food and DrugFigure 5 Joint swelling measurements (mm) as an indication of inflam
SiMAG-labelled mMSCs, unlabelled mMSCs and control groups over A) thre
after subtraction of the left knee control. Significant levels ** indicates P <0
RA, rheumatoid arthritis; SEM, standard error of the mean.Administration approved particles such as Endorem
(150 nm) [37] and Feraheme (30 nm) [36]. Contrary to
the above group of studies where MNP ranged in size
between 11 nm and 150 nm in diameter, Saldanha et al.
investigated the use of micron sized particles (1.63 μm) as a
potential tracking agent to monitor cartilage regeneration.
Rabbit MSC were labelled with a commercially available
particle and implanted within an ex vivo knee model
(bovine) and MR imaged using 3 T to monitor articular
cartilage regeneration [19].
From these studies, it is evident that tracking studies
have primarily focused on the rat or rabbit models where
surgical techniques are used to mimic trauma or osteoarth-
ritis. In addition, cells have generally been labelled with
a maximum particle size of 150 nm and seeded onto
hydrogel scaffolds prior to implantation. The end point
of such animal studies is often histological assessment.
Animal models, however, also allow for the investigation of
functional outcomes, such as the presence of inflammation.
Very few stem cell related studies actually monitor histo-
pathological features while assessing functional outcomes
and tracking cells in vivo.mation and RA progression. Comparing joint swelling between
e days and B) seven days. Data are mean ± SEM for the right knee
.01 and * indicates P <0.05. mMSCs, murine mesenchymal stem cells;
Figure 6 MRI in vivo cell tracking and histological evaluation of synovial joint. A) Signal profiles, B) corresponding coronal FLASH (day 3)
and GEFI (day 7) MRI scans, C) H & E sections of synovial joint highlighting location of SiMAG labelled cells by D i) CM- DIL (red) and DAPI (blue).
Fluorescent analysis and D ii) corresponding Prussian blue stain for i) group 1 (+ mMSCS, + SiMAG; three days, N = 6), ii) group 2 (+ mMSCS, +
SiMAG; seven days, N = 5), iii) group 3 (+ mMSCS, - SiMAG; three days, N = 6) and iv) group 6 (− fmMSCS, - SiMAG; seven days, N = 5).T, tibia;
F, Femur; M, meniscus. Bars = 100 μm. FLASH, fast low angle shot; GEFI, gradient-echo fast imaging; mMSCs, murine mesenchymal stem cells;
MRI, magnetic resonance imaging.
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Figure 7 Toluidine staining to demonstrate cartilage depletion within joint sections for i) group 1 (+ mMSCS, + SiMAG; three days,
N = 6), ii) group 3 (+ mMSCS,- SiMAG; three days, N = 6) and iii) group 5 (− mMSCS, - SiMAG; three days, N = 6). Bars = 100 μm. mMSCs,
murine mesenchymal stem cells.
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intracellular iron (Fe) content. This value is dependent
upon on a number of factors including particle size,
surface charge, labelling protocol and the rate of cell
proliferation [25,38]. In this study, a 24 hour serum-free
passive incubation method was applied. This method tends
to be limited to cells with a high degree of phagocytosis, a
property not exhibited by stem cells [39]. The addition of
transfection agents (TA) may thus be required to stimulate
phagocytosis [24]. Studies by Hill et al. and Saldanha et al.
have demonstrated the efficient uptake of micron scale
particles by MSCs via passive incubation without the use
of TA [19,23]. In this study, 1 μm, commercially available
particles, SiMAG, have been used and resulted in a
labelling efficiency of 80% with a total iron content of
20 pg of Fe/cell. This value is comparable to other
studies where internal Fe content ranged from 1 to 30 pg
of Fe/cell compared to a value of 0.1 pg of Fe/cell for
unlabelled cells [18,20].
Internalised Fe disrupts the local magnetic field causing a
shortening of T2 and T2*, thereby allowing SPION-labelled
cells to be visualised as signal voids (blackened marks) or
hypointense areas on MRI scans [19-25]. It is essential
to establish MRI visibility thresholds in terms of particle
concentration and cell number, both in vivo and in vitro
and to appreciate that the detection threshold is affected
by magnetic field strength and MRI acquisition parame-
ters [20]. In vitro detection threshold was set at a T2 of
0.0840 ± 0.002 ms corresponding to a minimal cell dose
of 100,000 (5 and 10 μg/ml) and particle concentration
of 1 μg/ml (300,000 cells). These are considered highly
acceptable values as similar studies by Jing et al. reported
a minimal cell dose of 5 × 105 MSCs when labelled with
25 μg/ml Feridex and the transfection agent protamine
sulphate [16]. As expected, T2 was seen to decrease with
increasing cell numbers and particle concentrations corre-
sponding to the increasing Fe content. T1 values were also
measured but little difference in T1 was noticed. Detection
thresholds were validated in vivo by implanting 300,000
cells labelled with 1, 5 and 10 μg/ml into each mouse knee
and MR imaged using GEFI T2 weighted sequences.Relaxivity measurements could not be taken due to the
inhomogeneities associated with biological tissue. Signal
intensity across the hypointense regions of the knee were
read, plotted and compared. The magnetic susceptibility
of an individual SPION results in a blooming artefact
which extends beyond the size of the individual particles
allowing small injections of particles to be amplified be-
yond the actual location making for practical identification
[20,23]. The effect of particle concentration on the bloom-
ing effect is clearly seen here. In mice injected with SiMAG
(5 and 10 μg/ml), significant loss in signal (61 and 78%,
respectively) was measured over a substantial area; however,
this signal loss was experienced over a greater area in
the mice injected with 10 μg/ml than in those injected
with 5 μg/ml. A less obvious drop in SI was observed
for mice injected with 1 μg/ml (20%) when compared to
the control mice.
Toxicity and safety is a major concern in the implemen-
tation of SPIONs in any cell-based therapy [34]. It thus
becomes necessary to investigate the viability, proliferation
and differentiation potential of SiMAG-labelled cells. A
vast number of studies have reported that the use of
SPIONs in conjunction with stem cells has little or no
effect on the proliferation and viability of cells [18,20,25].
SPIONs are considered to be inert and biocompatible
given the nature of Fe [18]. Fe is a naturally occurring
element in the human body playing an important role in
cellular metabolic processes, such as DNA synthesis,
oxygen transport and redox reactions [29,34]. The body is
therefore adapted for Fe metabolism and thus labelling
MSCs with SPIONs is not likely to affect the biological
properties of cells [29]. In high quantities, however, Fe can
possibly impair cell viability by damaging cell membranes,
proteins and DNA [28,29]. Therefore, it is important to ob-
tain a balance between Fe incorporation for the required
role and cell function [28]. Cell viability assays revealed
that cell viability was maintained in SiMAG-labelled
cell populations up to seven days post labelling with no
significant effect on cell proliferation capacity either.
Furthermore, FACS data demonstrated similar profiles for
SiMAG-labelled cells and unlabelled cells implying
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cell surface markers.
Currently, there is a debate regarding the differentiation
ability of cells once they have been labelled with SPIONS
[25]. Generally, studies have found that the osteogenic and
apidogenic potential of MSCs was maintained post SPION
labelling whilst there are conflicting reviews reported for
the differentiation of SPION labelled MSCs to chondro-
cytes [25,29]. Studies have shown that stem cells labelled
with Feridex (an FDA approved contrast) inhibited their
differentiation towards the chondrogenic lineage but this
was not the case for osteogenic and adipogenic lineages
[25,28,40]. Kostura et al. found that the presence of Feridex
interfered with the signalling pathway responsible for
driving chondrogenic differentiation [40]. In contrast,
Jasmin et al. reported that MCSs labelled with Feridex
underwent successful differentiation down all three lineages
(adipogenesis, chondrogenesis and osteogenesis) [30]. In a
study by Henning et al., it was shown that differentiation to
chondrocytes was dose dependent which may explain the
contrasting results [29]. Henning also suggested that the
use of a TA could mitigate this effect by encouraging the
internalisation of particles via an alternative mechanism
and further compartmentalization which might cause
less interaction with differentiation linked intracellular
substrates [29]. We have not been able to demonstrate
successfully the differentiation of BALB/c mMSCs to
chondrocytes in either labelled or unlabelled cells. In a
study by Chamberlain et al. BALB/c derived mMSCs were
shown to differentiate down osteogenic and adipogenic, but
not chondrogenic, lineages [26]. We cannot, therefore, con-
tribute the lack of chondrogenic potential to the presence
of SiMAG but to properties of the cells themselves. Import-
antly, we have shown that mMSCs labelled with 10 ug/ml
of SiMAG retain their capability to differentiate successfully
down osteogenic and adipogenic lineages.
The chosen model bears numerous similarities to the
human mode of the disease and is thus suitable for
predicating the efficacy and appropriateness of this ther-
apy in humans [41]. It must be noted that the rodent
version of this disease progresses at a faster rate than
does the human version. Therefore, any interventions are
monitored by assessing acute inflammation (macrophage,
lymphocyte and neutrophil infiltration) in terms of joint
swelling [3,41]. As expected, a significant decrease in joint
swelling was measured upon mMSC administration. In a
similar way, the administration of SiMAG-labelled mMSC
also resulted in a significant decrease in joint swelling with
no statistical difference between the mMSC groups. This
suggests that the immunomodulating properties of mMSC
labelled with SiMAG are maintained. Biological variation
between mice within groups accounts for the conflicting
rates of joint swelling progression between the two studies
where a significant drop in joint swelling was found onday two for the three day study but only on day three for
the seven day study. A limitation of this study in terms of
assessing the therapeutic effects of mMSCs in treating RA
would be the low N numbers of the study.
The therapeutic effects of mMSCs in the same model
of RA were assessed by Kehoe et al. (paper under re-
view). This study concluded that mMSCs are therapeutic
when injected into the joints of mice with AIA as dem-
onstrated by reduced levels of cartilage destruction.
Toluidine blue staining demonstrated far less cartilage
depletion in groups receiving either SiMAG labelled or
unlabelled mMSC when compared to control groups.
This suggests that the therapeutic potential of mMSCs
is not affected by SiMAG labelling. Although the mech-
anism of action is unknown, it is unlikely that the im-
planted cells are differentiating into chondrocytes and
repopulating the damaged area as no fluorescently la-
belled cells could be found within the articular cartilage,
corroborating findings by Kehoe et al. It has been sug-
gested by Kehoe et al. that the mechanism of repair is at-
tributed to a paracrine effect whereby the early MSC
treatment acts to prevent proteoglycan loss via the secre-
tion of factors influencing the activity of ADAMTS en-
zymes, an enzyme responsible for the cleaving of aggrecan
(an abundant proteoglycan in articular cartilage).
In terms of imaging and tracking, the blooming effect of
the particles and the application of T2 weighted sequences
(GEFI/FLASH) made for simple identification of the
implanted SiMAG-labelled cell population and the location
was easily identified as the synovial cavity up to seven days
post implantation. This was shown graphically by compar-
ing the SI of joints treated with SiMAG-labelled cells to
unlabelled cells and to untreated knees, where a signifi-
cant loss of signal was measured, further highlighting the
position of cells. This was further verified via histological
analysis where DiI labelled cells were clearly seen within
the synovial joint up to seven days post implantation.
The use of MRI has a dual purpose. Not only can it be
used to image and track implanted cells, but its ability to
distinguish between cartilage and bone [3] can be used
to assess the defect and determine the extent of cartilage
repair. The amount of fill in the image could reflect the
extent of repair while comparing the signal of the new
graft with surrounding tissue could indicate the maturity
of the graft [42]. As mentioned previously, the blooming
effect of the cells allows for the simple identification of
cells in vivo. However, when applied to such a small
joint, it is impossible to analyse tissue repair as it blocks
all surface anatomy.Conclusions
Although this study has not assessed the extent of cartilage
repair, there is no reason to believe that the presence of
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seen in a similar study from Kehoe et al. (under review).
Regenerative medicine and tissue engineering thrive on
the cross collaboration of multiple fields to aid in the
application of stem cell based therapies. This often
involves the development and implementation of enabling
technologies (as described in the manuscript) in line with
regulatory bodies to bring stem cell based therapies closer
to the clinic. Feridex and Endorem are examples of FDA
approved, iron-based MRI contrast agents that have
previously been used in conjunction with TAs in similar
studies. Unfortunately, these particles have recently been
taken off the market [34] with no other suitable replace-
ments. Therefore, the need to identify and implement a
new particle is necessary. The ideal labelling agent should
allow for the repetitive, non-destructive and non-invasive
long term tracking of implanted cells while maintaining
cellular function at a realistic dose within a clinically
relevant system [22]. SiMAG has been shown successfully
to maintain cellular function at realistic doses within a
clinically relevant system; however, its application in long
term tracking has yet to be investigated. This manuscript
thus highlights the potential of SiMAG to be used and
adapted as a suitable agent for the imaging and tracking of
cell populations via MR imaging in the clinical translation
of a wide range of cell therapies.
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